1月8日，医疗ETF（159828）涨超1%，行业进入创新兑现与全球布局的关键阶段。 医疗ETF（159828）跟踪的是中证医疗指数（399989），该指数从沪深市场中选取涉及医疗器械、医疗 服务、医疗信息化等领域的上市公司证券作为指数样本，以反映医疗主题上市公司的整体表现。该指数 聚焦医药卫生行业，指数具有较高的成长属性和行业集中度，受到老龄化趋势、消费升级及政策导向的 影响。 （文章来源：每日经济新闻） 太平洋证券指出，医药生物行业已进入创新兑现与全球布局的关键阶段，产业周期、政策周期与资本周 期在2026年有望形成共振，中国创新药发展正从"创新叙事"进入"价值兑现"阶段，有望迎来业绩拐点与 估值重塑。重点关注以ADC、双/多特异性抗体、细胞与基因治疗、小核酸等为代表的下一代创新疗 法。医疗器械方面，集采影响日渐减弱，政策覆盖范围过半，其中高值耗材、低值耗材、体外诊断、医 疗设备的覆盖率分别为58%、35%、23%、3%。国产械企在部分超高端领域实现突破，如光子计数 CT、主动脉反流瓣等，叠加出海保持快速增长（2025年1-11月医疗器械出口额同比增长7.3%），相关 企业有望陆续迎来业绩修复。建议关注集 ...

新华社北京1月6日电 题：创新破局 国产高端医疗器械崛起正当时 新华社记者戴小河 2025年，国家药监局共批准76个国产创新医疗器械上市，数量连续3年维持高位，覆盖人工智能、 肿瘤放射治疗、生物医用材料等多个前沿领域。 这组国家药监局1月6日公布的数据，清晰勾勒出我国高端医疗器械产业的转型图景。 从曾经的高端诊疗设备依赖进口到如今"中国智造"批量涌现，从临床补充选项成长为核心治疗装 备，从技术跟随模仿迈向源头创新引领，在政策精准赋能、技术持续攻坚、市场需求牵引的共同作用 下，我国高端医疗器械产业正经历从低水平重复到创新提质的蝶变。 近年来，国家药监局持续深化审评审批制度改革，构建起创新特别审查、优先审批等多元化通道， 将监管服务重心向研发阶段前移，形成"提前介入、一企一策、全程指导、研审联动"的工作机制，让创 新产品上市之路更顺畅。 "改革的核心是为创新松绑、为质量护航。"国家药监局器械注册司司长吕玲表示，通过优化特殊审 批程序、完善分类命名原则、健全沟通指导机制等关键举措，对人工智能、医用机器人、新型生物材料 等高端医疗器械给予重点支持。2025年12月又进一步聚焦脑机接口、高端影像设备等核心领域出台优先 ...

Core Points - The Liaoning May Day Labor Award ceremony was held on November 11, recognizing outstanding collectives and individuals in the province for their contributions to economic revitalization [1] - A total of 50 units, including Shenyang Yuanda Compressor Co., Ltd., received the Liaoning May Day Labor Award, while 400 workers, including Ma Chaoyang, were awarded the Liaoning May Day Labor Medal [1] - The event emphasized the importance of labor spirit and encouraged workers to actively participate in economic development and high-quality growth initiatives [1] Summary by Categories - **Recognition and Awards** - 50 units awarded the Liaoning May Day Labor Award, including Shenyang Yuanda Compressor Co., Ltd. [1] - 400 individuals awarded the Liaoning May Day Labor Medal, including Ma Chaoyang [1] - 50 collectives, such as the Neusoft Medical Photon Counting CT R&D team, received the Liaoning Worker Pioneer title [1] - **Call to Action** - Recognized collectives and individuals are urged to cherish their honors and continue their efforts [1] - Workers are encouraged to implement the decisions of the Central Committee and engage in economic construction [1] - Emphasis on overcoming challenges in major strategies, projects, and key industries to promote high-quality development [1] - **Leadership and Support** - Local party committees are called to enhance leadership over union activities and create favorable conditions for unions to fulfill their roles [1]

Core Viewpoint - Siemens Healthineers showcases its advanced technologies and strategic initiatives at the 8th China International Import Expo, emphasizing its commitment to local innovation and partnerships in the healthcare sector [1][11]. Group 1: Strategic Positioning - Siemens Healthineers maintains growth through a forward-looking strategy, focusing on "National Intelligence Innovation" and transitioning from a product provider to a value partner [2][5]. - The "National Intelligence Innovation" strategy emphasizes local production and innovation, with a goal of achieving full product line localization [4][11]. Group 2: Product and Innovation - The company has nearly achieved full localization of its product line, with plans for local mass production of photon counting CT devices by 2026 [4]. - Siemens Healthineers collaborates with local medical institutions to develop innovative solutions, creating a closed loop from clinical needs to product implementation [5][6]. Group 3: AI Integration - The company integrates AI deeply into its devices and clinical applications, showcasing advancements in AI-assisted diagnostics and imaging technologies at the expo [7][8]. - Siemens Healthineers aims to create an "automated driving" experience for imaging devices, enhancing efficiency and accuracy in clinical settings [8][10]. Group 4: Future Directions - The new five-year plan focuses on closer clinical integration, deeper collaboration, and sustainability, aiming to become a core partner in disease management and hospital administration [13]. - Siemens Healthineers is committed to fostering local innovation ecosystems and supporting the growth of domestic medical technology startups [12][11].

Core Insights - The China International Import Expo (CIIE) has evolved into a crucial platform for multinational companies to integrate into the Chinese market and share development opportunities since its inception in 2018 [1][14] - Siemens Healthineers has participated in the CIIE for eight consecutive years, showcasing its commitment to the Chinese market and emphasizing the importance of innovation and local collaboration [2][14] Company Strategy - Siemens Healthineers aims to combine global innovations with local clinical needs through its "National Intelligence Innovation" strategy, transitioning from global technology introduction to local innovation output [2][7] - The company has established a comprehensive medical ecosystem in China, focusing on R&D, production, clinical application, and patient care [7][8] Product Innovations - At this year's CIIE, Siemens Healthineers launched several groundbreaking products, including the new photon-counting CT family, which will enhance China's manufacturing capabilities in high-end medical equipment [3][4] - The ARTIS icono ceiling Xpand system significantly reduces imaging time in tumor interventions and stroke emergencies, improving clinical efficiency [6][12] Local Development - Siemens Healthineers has invested over 1 billion RMB in a new high-end medical equipment R&D and manufacturing base in Shenzhen, expected to triple its current scale by 2027 [7][8] - The company has localized over 130 products and filed more than 1,000 patents in China, demonstrating its commitment to local innovation [7][8] Market Potential - China is a key market for Siemens Healthineers, with a projected increase in the middle-income population from 400 million to 800 million over the next decade, driving demand for high-end medical services [12][14] - The company plans to focus on four core disease areas: cardiovascular diseases, cancer, neurodegenerative diseases, and stroke, aligning with national health strategies [12][13] Sustainability Efforts - Siemens Healthineers is committed to green and sustainable development, with initiatives like the DryCool technology that significantly reduces energy consumption and environmental impact [10][11] - The company aims for net-zero emissions by 2050 and is actively working on establishing green standards in the medical equipment industry [10][11]

Core Insights - The establishment of the Sci-Tech Innovation Board (STAR Market) has significantly enhanced China's capital market's ability to support technological innovation, with 592 listed companies and total fundraising exceeding 1.1 trillion yuan by October 2025 [1][3] - The STAR Market has demonstrated strong growth, with a compound annual growth rate (CAGR) of 18% in revenue and 9% in net profit for listed companies over the past five years [3][4] - The board has successfully fostered a vibrant ecosystem for hard technology, with over 80% of companies in emerging industries such as new-generation information technology and biomedicine [4][5] Company Performance - As of 2025, 22 out of 57 unprofitable companies listed on the STAR Market have achieved profitability, indicating a positive trend in financial performance [3] - The integrated circuit sector has over 120 listed companies, with revenue and net profit growth of 27% and 83% respectively in the first three quarters of 2025 [4] - In the biopharmaceutical sector, 21 out of 22 companies have received approval for 48 drugs/vaccines, contributing significantly to the innovation landscape [4] R&D Investment - The total R&D investment by STAR Market companies reached 1,680 billion yuan in 2024, more than three times their net profit [5] - In the first three quarters of 2025, R&D investment amounted to 1,133.45 billion yuan, a year-on-year increase of 9.01% [5] - The average number of invention patents per company on the STAR Market is 230, with 30% of companies having products or projects that are industry-first [5][6] Ecosystem Development - The STAR Market has created a virtuous cycle of "technology-industry-capital," enhancing the efficient allocation of innovative resources [7] - Over 60% of the founding teams of STAR Market companies consist of scientists or industry experts, fostering a strong innovation culture [7] - The market has seen a significant increase in cash dividend proposals, with a total of 38.8 billion yuan in dividends planned for 2024 [8] Institutional Innovation - The STAR Market has pioneered various institutional innovations, including diverse listing standards and mechanisms for rapid financing, which serve as a model for other markets [9] - Recent reforms have expanded the scope of the STAR Market to include more cutting-edge fields, enhancing its inclusivity [9] - The growth of the STAR Market's "growth layer" has accelerated, with companies showing revenue growth of 35.09% and a median R&D intensity of 44.34% [9] Future Outlook - The Shanghai Stock Exchange aims to further leverage the STAR Market as a testing ground for identifying high-quality tech companies, particularly in emerging fields like artificial intelligence and aerospace [10]

Core Viewpoint - The establishment of the Sci-Tech Innovation Board (STAR Market) has significantly contributed to the development of China's capital market, particularly in supporting technological innovation and the growth of "hard technology" companies over the past seven years [1][3]. Group 1: Market Development and Performance - As of October 2025, the STAR Market has gathered 592 listed companies, with a cumulative IPO fundraising scale of 934.6 billion yuan and total financing exceeding 1.1 trillion yuan, playing a crucial role in nurturing new productive forces and upgrading the modern industrial system [1]. - The compound annual growth rates for operating income and net profit attributable to shareholders of STAR Market companies over the past five years are 18% and 9%, respectively, indicating strong growth potential [3]. - Among the 57 unprofitable companies at the time of listing, 22 have achieved profitability, showcasing a trend of successful transitions from research and development to market success [3]. Group 2: Industry Focus and Innovation - The STAR Market has maintained a focus on "hard technology," with over 80% of listed companies in emerging industries such as new-generation information technology, biomedicine, and high-end equipment manufacturing [5]. - Key industries like integrated circuits and biomedicine have seen significant clustering effects, with over 120 listed companies in the integrated circuit sector, contributing to a complete and collaborative innovation ecosystem [6]. - In the integrated circuit sector, revenue and net profit for 119 companies that disclosed Q3 reports in 2025 grew by 27% and 83% year-on-year, respectively, with net profit for chip design companies soaring by 141% [6]. Group 3: Research and Development Investment - In 2024, total R&D investment by STAR Market companies reached 168 billion yuan, more than three times their net profit; in the first three quarters of 2025, R&D investment reached 113.3 billion yuan, a year-on-year increase of 9.01% [7]. - The STAR Market has generated over 130,000 invention patents, with an average of 230 patents per company, and 30% of companies have products or projects that are industry-first [7]. Group 4: Ecosystem and Capital Integration - The STAR Market has successfully established a virtuous cycle of "technology-industry-capital," enhancing the efficient allocation of innovative resources [10]. - Approximately 90% of STAR Market companies received venture capital investment before going public, indicating a strong trend towards early-stage investment in hard technology [11]. - The STAR Market has developed a comprehensive index system, with over 100 ETFs listed, and the total scale of index tracking products exceeding 330 billion yuan, making it a flagship index for hard technology investments [11]. Group 5: Institutional Innovation and Reforms - As a pioneer in the registration system reform, the STAR Market has implemented various innovative practices in issuance, listing, and trading, providing valuable experience for other market segments [14]. - Recent reforms, including the "1+6" measures, have further enhanced the inclusivity of the system, supporting the growth of companies in cutting-edge fields like artificial intelligence [14][15]. - The STAR Market has also accelerated the development of the "growth layer" for innovative companies, with significant increases in revenue and R&D investment among these firms [14].

Group 1 - Gilead Sciences showcased 13 innovative drugs at the China International Import Expo, emphasizing their commitment to creating a healthier world [1] - The long-acting HIV pre-exposure prophylaxis drug, Lenacapavir, is the first of its kind approved globally, requiring administration only twice a year, and has recently been applied in China [1] - The expo featured numerous cutting-edge medical technologies, including Siemens Healthineers' photon-counting CT and Medtronic's first rechargeable closed-loop spinal cord stimulation system [1] Group 2 - This year's expo saw an increase in reception and negotiation spaces for pharmaceutical companies, indicating a growing emphasis on business interactions [2] - A centralized signing hall was established for procurement activities, with nearly 200 buyers from central enterprises and health authorities expected to engage in over 70 signing events [2] - The overall theme of the expo is focused on collaboration to create a healthier world through new products, technologies, and services [3]

Group 1 - Gilead Sciences showcased its innovative drug, Lenacapavir, which is the world's first long-acting HIV pre-exposure prophylaxis approved for administration twice a year, recently launched in China [1] - The exhibition highlighted 13 innovative drugs launched by Gilead in China, emphasizing the company's commitment to improving drug accessibility and promoting health equity [1] - The event featured various cutting-edge medical technologies, including Siemens Healthineers' photon-counting CT and Medtronic's first-ever rechargeable closed-loop spinal cord stimulation system [1][2] Group 2 - This year's exhibition saw an increase in reception and negotiation spaces for pharmaceutical companies, indicating a growing emphasis on business interactions [2] - A centralized signing hall was established for nearly 200 buyers from central enterprises and health authorities to engage in over 70 signing activities with exhibitors [2] - The overarching theme of the event was to collaboratively "create a healthier world," showcasing new products, technologies, and services [3]

Group 1 - Gilead Sciences showcased 13 innovative drugs and projects aimed at improving drug accessibility and promoting health equity at the China International Import Expo [1] - The innovative drug Lenacapavir, a long-acting HIV pre-exposure prophylaxis approved for administration twice a year, has recently been approved in China and completed its first application [1] - The expo featured numerous cutting-edge medical technologies, including Siemens Healthineers' photon-counting CT and Medtronic's first-ever rechargeable closed-loop spinal cord stimulation system [1] Group 2 - This year's expo saw an increase in reception and negotiation spaces for pharmaceutical companies compared to previous years [2] - A centralized signing hall was established for nearly 200 buyers from central enterprises and health authorities to engage in over 70 signing activities with exhibitors [2] - The overarching theme of the expo is to collaboratively "create a healthier world" through new products, technologies, and services [3]